Notice of Results

Tissue Regenix

17/09/2025 07:00

RNS Number : 5852Z

Tissue Regenix Group PLC

17 September 2025

 

 Tissue Regenix Group plc

('Tissue Regenix' or the 'Group')

 

Notice of Results

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms that further to the announcement on 8 September 2025, the Company will now issue its interim results on Tuesday 30 September.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4pm BST on Tuesday 30 September. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the presentation here:  

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

 

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

 

For more information:

 

Tissue Regenix Group plc
www.tissueregenix.com
Daniel Lee, Chief Executive Officer
Brandon Largent, Interim Chief Financial Officer
via Walbrook PR
Cavendish Capital Markets Limited(Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Edward Whiley
Tel: +44 (0) 20 7466 5000
Nigel Birks - Life Science Specialist Sales
Harriet Ward - ECM
Walbrook PR (Financial PR and IR)
Tel: +44 (0)20 7933 8780
Alice Woodings
TissueRegenix@walbrookpr.com


 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NORMZGMLVVFGKZM